Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

NCT01572792 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

921

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
DRUG: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
DRUG: Aclidinium bromide
DRUG: Formoterol Fumarate
DRUG: Placebo

Sponsor

AstraZeneca